Physician profile
Reena Gupta
NPI 1144587544
$35,715.07
in general payments reported to CMS, 2019-2025
27 companies · $20K in 2025
The $20K reported for 2025 was more than what 97% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $715 · 2020: $838 · 2021: $828 · 2022: $4,508 · 2023: $3,768 · 2024: $4,774 · 2025: $20K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $15K · Food and Beverage: $10K · Travel and Lodging: $3,982 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $14,717.50 |
| Food and Beverage | $10,026.74 |
| Travel and Lodging | $3,981.92 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaukos Corporation | $16,716.35 | 2019-2025 | Epioxa, Travoprost Intraocular Implant - Idose, Ce-Marked Kxla System |
| Rxsight INC | $5,082.97 | 2022-2025 | Rxsight Injector Cartridge, Rxsight Injector Handpiece, Rxsight Contact Lens |
| Biotissue Holdings INC. | $4,054.92 | 2021-2025 | |
| Tarsus Pharmaceuticals, INC. | $2,206.34 | 2024-2025 | Xdemvy |
| Bausch & Lomb Americas INC. | $1,905.41 | 2022-2025 | Envista Mx60 Iol, Envista Aspire Iol, Miebo |
| Dompe US, INC. | $1,244.30 | 2019-2025 | Oxervate |
| Mallinckrodt Hospital Products INC. | $1,079.14 | 2021-2025 | Acthar |
| Alcon Vision LLC | $732.67 | 2023-2025 | Tryptyr, Clareon, Eysuvis |
| Sight Sciences, INC. | $631.31 | 2020-2025 | Omni Surgical System, Sion Surgical Instrument |
| Allergan, INC. | $334.92 | 2019-2022 | |
| New World Medical,INC. | $260.71 | 2024 | Kahook Dual Blade, Ahmed Glaucoma Valve, Clearpath |
| Oyster Point Pharma, INC. | $204.21 | 2022-2025 | Tyrvaya |
| Novartis Pharmaceuticals Corporation | $193.40 | 2019-2022 | |
| Harrow Eye, LLC | $173.08 | 2024-2025 | Vevye, Iheezo |
| Kala Pharmaceuticals, INC. | $147.56 | 2019-2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Surgical Vision, INC. | $145.59 | 2025 | Tecnis Iol |
| Rayner Intraocular Lenses Limited | $124.75 | 2024 | Rayone Emv, Rayone Aspheric, Rayone Spheric |
| Genentech USA, INC. | $117.13 | 2019 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $98.11 | 2019-2020 | |
| Amgen INC. | $68.37 | 2024-2025 | Tepezza |
| Abbvie INC. | $65.31 | 2022-2023 | |
| Carl Zeiss Meditec, INC. | $36.11 | 2024 | |
| Sun Pharmaceutical Industries INC. | $35.41 | 2025 | |
| Halozyme INC | $25.97 | 2024 | Hylenex Recombinant |
| Alimera Sciences, INC. | $16.66 | 2024 | Yutiq, Iluvien |
| Aerie Pharmaceuticals, INC. | $14.37 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Reena Gupta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.